stereotaxis

James M. Stolze, chief financial officer of Stereotaxis, said the building had worked out well.

Stereotaxis Inc sell a range of compatible equipment, including a new compatible irrigated catheter.

This technique employed by companies such as Stereotaxis [1] is unlike other robotic navigation techniques.

The Bordeaux group have published in abstract form a similar experience using the stereotaxis system in 28 patients, and comparing its use to manual procedures over the same period.

Hamilton AJ, Hadley MN: "Spinal Stereotaxis and Radiosurgery".

Patrick J. Kelly, "Introduction and Historical Aspects", Tumor Stereotaxis, Philadelphia: W.B. Saunders Company (1991)

Cortex remained more of a concept than a reality until two years ago when Mr. Dubinsky learned that Stereotaxis, a medical device company housed in a nearby incubator facility, was looking to relocate.

The building, which Cortex owns, currently is 80 percent leased to two tenants, Stereotaxis and the Center for Applied Nanomedicine, a division of the Washington University School of Medicine.

The hospital recently upgraded its catheter lab with a remote magnetic navigation system called the Niobe, manufactured by Stereotaxis, positioning the hospital as one of the worlds most advanced providers of interventional cardiology services.

The engineering was developed at the University of Virginia, and the patent rights were later acquired by Stereotaxis, Inc. to market and develop a magnetic navigation system, according to its 2005 10-K filing with the SEC.

Magnetic irrigated catheters for Stereotaxis's Niobe MNS have been recently approved by the FDA on February 26, 2009, and the catheters have been commercially available in Europe since November, 2008.

The cardiac catheterization procedure may be performed by hand, or with the help of a robotic catheterization system such as Stereotaxis remote magnetic navigation (RMN) or the Hansen Medical Sensei robotic catheter system.

The system was initially developed at the University of Virginia, and was acquired by Stereotaxis Inc. (St. Louis, Missouri, USA) in 2005 and named the Niobe system (now the Niobe II).

Further reports are awaited to confirm whether the redesign of the Stereotaxis irrigated ablation catheters has overcome the issues of char formation, and whether further developments in the Niobe II system will make pulmonary vein isolation achievable for a greater proportion of patients than is currently the case.